Redmile Group (ATTO) reports Series B preferred stake convertible into 782,854 shares
Rhea-AI Filing Summary
Redmile Group, LLC and affiliated entities report initial beneficial ownership in Attovia Therapeutics, Inc. through holdings of Series B Preferred Stock. This preferred stock is convertible into 782,854 shares of common stock and is held indirectly via Redmile Biopharma Investments III, L.P.
The Series B Preferred Stock is convertible into common stock for no consideration at any time at the holder's election or automatically upon the closing of Attovia's initial public offering, and is redeemable at the holder's option beginning in March 2035 at the applicable original issue price plus declared but unpaid dividends. The security has no expiration date. A prior 1-for-9.29 reverse stock split of Attovia's common stock was effected on July 29, 2026. The reporting persons state that they may be deemed beneficial owners through investment management relationships and disclaim beneficial ownership beyond any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Redmile Group, LLC, Green Jeremy, Redmile Biopharma Investments III, L.P.
Role
10% Owner | 10% Owner | 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series B Preferred Stock F2, F1, F3 | -- | -- | -- |
Holdings After Transaction:
Series B Preferred Stock — 782,854 shares (Indirect, See Footnote)
Footnotes (3)
- F1. Reflects the 1-for-9.29 reverse stock split of the Issuer's outstanding common stock effected on July 29, 2026.
- F2. The Series B Preferred Stock is convertible into shares of the Issuer's common stock at the applicable conversion rate for no consideration (i) at any time at the holder's election, or (ii) automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock is redeemable at the option of the holder beginning in March 2035 based on the applicable original issue price, plus all declared but unpaid dividends thereon. The Series B Preferred Stock has no expiration date.
- F3. These securities are directly owned by Redmile Biopharma Investments III, L.P., which is managed by Redmile Group, LLC ("Redmile"), and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicle. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Key Figures
Underlying common shares: 782,854 shares
Reverse stock split ratio: 1-for-9.29
Redemption start: March 2035
3 metrics
Underlying common shares
782,854 shares
Shares of Attovia common stock underlying the reported Series B Preferred Stock
Reverse stock split ratio
1-for-9.29
Reverse stock split of Attovia common stock effected on July 29, 2026
Redemption start
March 2035
Series B Preferred Stock redeemable at holder's option beginning in March 2035
Key Terms
reverse stock split, convertible, original issue price, beneficially owned, +1 more
5 terms
reverse stock split financial
"Reflects the 1-for-9.29 reverse stock split of the Issuer's outstanding common stock"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
convertible financial
"The Series B Preferred Stock is convertible into shares of the Issuer's common stock"
A convertible is a type of investment that starts as a loan or preferred stake (like a bond or preferred share) but can be exchanged for common shares of the company at a set price or under certain conditions. It matters to investors because it offers a mix of steady income and downside protection like a loan, plus the upside of stock ownership if the company does well—similar to holding a coupon that you can trade for a full ticket if the event becomes valuable.
original issue price financial
"redeemable at the option of the holder based on the applicable original issue price"
beneficially owned financial
"may be deemed beneficially owned by Redmile as investment manager"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
pecuniary interest financial
"disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest"
FAQ
What ownership in Attovia Therapeutics (ATTO) does Redmile report on this Form 3?
Redmile-associated entities report Series B Preferred Stock that is convertible into 782,854 shares of Attovia common stock, held indirectly through Redmile Biopharma Investments III, L.P., with Redmile as investment manager and Jeremy Green as principal.
How can the reported Series B Preferred Stock in Attovia (ATTO) be converted?
The Series B Preferred Stock is convertible into Attovia common stock for no consideration at any time at the holder's election, or automatically upon the closing of Attovia's initial public offering, based on the applicable conversion rate.
When is the Series B Preferred Stock in Attovia (ATTO) redeemable by the holder?
The Series B Preferred Stock is redeemable at the option of the holder beginning in March 2035, based on the applicable original issue price plus all declared but unpaid dividends on the shares being redeemed.
What did Attovia Therapeutics (ATTO) disclose about its reverse stock split?
The filing notes that Attovia effected a 1-for-9.29 reverse stock split of its outstanding common stock on July 29, 2026. The reflected common share numbers, including the 782,854 underlying shares, take that reverse split into account.
Who is deemed to beneficially own the reported Attovia (ATTO) securities?
The securities are directly owned by Redmile Biopharma Investments III, L.P., managed by Redmile Group, LLC, and may be deemed beneficially owned by Redmile and Jeremy Green. They disclaim beneficial ownership beyond their pecuniary interest.
Does the Series B Preferred Stock in Attovia (ATTO) have an expiration date?
No. The disclosure states that the Series B Preferred Stock has no expiration date. It remains outstanding unless converted into common stock or redeemed at the holder's option beginning in March 2035.
AI-generated analysis. How Rhea-AI works. Not financial advice.
